LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
Rhea-AI Summary
LENSAR (Nasdaq: LNSR) reported second quarter 2026 revenue of $16.5 million, up 18% year over year, with recurring revenue of $13.7 million, up 20% and representing 83% of total revenue. Procedure revenue rose 23% to $10.2 million on procedure volume of 58,682, up 13% versus Q2 2025.
The total laser installed base reached 445 systems, including 215 ALLY Robotic Cataract Laser Systems, a 30% increase year over year, driven by 10 ALLY placements in Q2 and a backlog of 13 systems. LENSAR delivered net income of $3.5 million versus a $1.8 million loss and Adjusted EBITDA of $3.6 million versus a $0.3 million loss. Cash, cash equivalents and investments were $13.6 million as of June 30, 2026, compared with $18.0 million at December 31, 2025.
Positive
- Total revenue $16.5M in Q2 2026, up 18% year over year
- Recurring revenue $13.7M in Q2 2026, up 20% and 83% of total
- Procedure revenue $10.2M in Q2 2026, up 23% year over year
- Procedure volume 58,682 in Q2 2026, up 13% from 52,100
- ALLY installed base 215 systems, up 30% year over year with 10 Q2 placements
- Net income $3.5M in Q2 2026 versus a $1.8M loss in Q2 2025
- Adjusted EBITDA $3.6M in Q2 2026 versus a $0.3M loss in Q2 2025
- Current liabilities reduced to $19.6M at June 30, 2026 from $40.6M at December 31, 2025
- Warrant liabilities reduced to $15.0M from $40.2M, improving balance sheet structure
- Stockholders’ equity improved to positive $14.9M from a $26.0M deficit at year-end 2025
Negative
- Cash, cash equivalents and investments decreased to $13.6M at June 30, 2026 from $18.0M at December 31, 2025
- Inventories increased to $24.9M from $21.5M, tying up additional working capital
- System revenue for the first six months declined to $3.6M from $5.2M in the prior-year period
News Explained
At June 30, LENSAR’s balance sheet showed 12,282 on the common-share line and 20 on the Series A preferred-share line, with a $20,000 liquidation preference.
The August 13 results release reports the completed quarter ended
The common-share line showed
If the higher common count reflects additional shares, the supplied dilution definition means a holder that did not add shares would own a smaller percentage; this release does not identify the change's mechanism.
The release also reports
Market reaction after 2Q26 earnings report: LNSR +22.57%
Following this news, LNSR has gained 22.57%, reflecting a significant positive market reaction. Argus tracked a peak move of +23.5% during the session. Our momentum scanner has triggered 22 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $7.71. Trading volume is exceptionally heavy at 13.1x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Q1 earnings report | Positive | +7.8% | Revenue growth, positive net income, and continued ALLY installed-base expansion |
| Mar 31 | Q4 earnings report | Positive | +1.5% | Recurring-revenue growth, installed-base expansion, and retained merger deposit |
| Nov 06 | Q3 earnings report | Negative | -8.6% | Net loss, higher expenses, and acquisition-related merger costs |
| Aug 07 | Q2 earnings report | Positive | -1.5% | Revenue and procedure-volume growth despite a reported net loss |
| May 08 | Q1 earnings report | Positive | -0.1% | Revenue and procedure-volume growth despite a substantial net loss |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with three aligned outcomes and two divergences across the selected history.
Key Terms
adjusted ebitda financial
warrant liabilities financial
non-gaap financial measure financial
redeemable convertible preferred stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026
Second Quarter Recurring Revenue was
Total Laser Installed Base Climbs to 445 Systems, Driven by
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.
“In all metrics we delivered a significant second quarter, highlighted by
LENSAR Q2 2026 Financial Summary
| Metric | Q2 2026 | Q2 2025 | % Change |
| Revenue | + | ||
| Recurring revenue | + | ||
| Procedure revenue | + | ||
| Procedure volume | 58,682 | 52,100 | + |
| Recurring revenue % | + | ||
| Total Laser Installed Base | 445 | 410 | + |
| Total ALLY Installed Base | 215 | 165 | + |
| Net Income (Loss) | N/M | ||
| Adjusted EBITDA | N/M | ||
| *N/M = Not meaningful due to change from a loss to positive earnings. | |||
Second Quarter 2026 Financial Results
In addition to the revenue growth summarized above, during the three months ended June 30, 2026, the Company placed 10 ALLY Systems, bringing the total installed ALLY base to approximately 215 at quarter end. As of June 30, 2026, the Company had a backlog of 13 ALLY Systems pending installation.
The following table provides information about revenue and recurring revenue, which we consider to be all components of our revenue except for the sales of our systems:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (Dollars in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| System | $ | 2,809 | $ | 2,576 | $ | 3,645 | $ | 5,208 | ||||||||
| Recurring revenue: | ||||||||||||||||
| Procedure | 10,233 | 8,334 | 19,473 | 16,620 | ||||||||||||
| Lease | 1,772 | 1,645 | 3,453 | 3,529 | ||||||||||||
| Service | 1,681 | 1,380 | 3,352 | 2,737 | ||||||||||||
| Total recurring revenue | 13,686 | 11,359 | 26,278 | 22,886 | ||||||||||||
| Total revenue | $ | 16,495 | $ | 13,935 | $ | 29,923 | $ | 28,094 | ||||||||
| Recurring revenue % | 83 | % | 82 | % | 88 | % | 81 | % | ||||||||
The following table provides information about procedure volume:
| 2026 | 2025 | 2024 | ||||||||||
| Q1 | 54,094 | 52,347 | 39,486 | |||||||||
| Q2 | 58,682 | 52,100 | 42,203 | |||||||||
| Total | 112,776 | 104,447 | 81,689 | |||||||||
Net income and Adjusted EBITDA increased due to improved revenue, lower operating expenses, and a
Cash, cash equivalents, and investments totaled
Conference Call
LENSAR management will host a conference call and live webcast to discuss the results and provide an update on the Company’s go-forward strategy today, August 13, 2026, at 8:30 a.m. ET.
To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available for 30 days.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding trends in worldwide procedure volume, ALLY’s commercialization and the Company’s operational and financial performance and long-term strategic goals. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.
Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: any anticipated effects of the termination of the agreement governing the merger on the value of our common stock; the outcome of any legal proceedings that may be instituted against us and others relating to the merger; our history of operating losses and ability to achieve or sustain profitability; our ability to develop, receive and maintain regulatory clearance or certification of and successfully commercialize the ALLY System and to maintain our LENSAR Laser System; the impact to our business, financial condition, results of operations and our suppliers and distributors as a result of global macroeconomic conditions; the willingness of patients to pay the price difference for our products compared to a standard cataract procedure covered by Medicare or other insurance; our ability to grow our U.S. sales and marketing organization or maintain or grow an effective network of international distributors; our future capital needs and our ability to raise additional funds on acceptable terms, or at all; the impact to our business, financial condition and results of operations as a result of a material disruption to the supply or manufacture of our systems or necessary component parts for such system or material inflationary pressures or enacted tariffs affecting pricing of component parts; our ability to compete against competitors that have longer operating histories, more established products and greater resources than we do; our ability to address the numerous risks associated with marketing, selling and leasing our products in markets outside the United States; the impact to our business, financial condition and results of operations as a result of exposure to the credit risk of our customers; our ability to accurately forecast customer demand and manage our inventory levels; the impact to our business, financial condition and results of operations if we are unable to secure adequate coverage or reimbursement by government or other third-party payors for procedures using our ALLY System or our other products, or changes in such coverage or reimbursement; the impact to our business, financial condition and results of operations of product liability suits brought against us; risks related to government regulation applicable to our products and operations; and risks related to our intellectual property and other intellectual property matters. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.
All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
| Contacts: | Lee Roth |
| Mike Rossi, Interim CFO | Burns McClellan for LENSAR |
| ir.contact@lensar.com | lroth@burnsmc.com |
Non-GAAP Financial Measures: The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA. EBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is included in this filing because we believe that EBITDA provides meaningful supplemental information for investors regarding the performance of our business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. We believe Adjusted EBITDA, which is defined as EBITDA and further excluding stock-based compensation expense, change in fair value of warrant liabilities, and acquisition-related income and costs provides meaningful supplemental information for investors when evaluating our results and comparing us to peer companies as stock-based compensation expense and change in fair value of warrant liabilities are significant non-cash charges, and acquisition-related income and costs are not recurring. We use these non-GAAP financial measures in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures we use may not be directly comparable to similarly titled measures of other companies. Investors should not consider our non-GAAP financial measures in isolation or as a substitute for an analysis of our results as reported under GAAP.
Reconciliations of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (Dollars in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income (loss) | $ | 3,535 | $ | (1,764 | ) | $ | 39,867 | $ | (29,109 | ) | ||||||
| Less: Interest income | (171 | ) | (193 | ) | (316 | ) | (352 | ) | ||||||||
| Add: Depreciation expense | 878 | 865 | 1,782 | 1,709 | ||||||||||||
| Add: Amortization expense | 228 | 230 | 457 | 462 | ||||||||||||
| EBITDA | 4,470 | (862 | ) | 41,790 | (27,290 | ) | ||||||||||
| Add: Stock-based compensation expense | 347 | 766 | 1,037 | 1,420 | ||||||||||||
| Add: Change in fair value of warrant liabilities | (1,230 | ) | (4,332 | ) | (25,178 | ) | 17,382 | |||||||||
| Add: Acquisition-related costs | — | 4,174 | (4,373 | ) | 8,399 | |||||||||||
| Less: Acquisition-related income | — | — | (10,000 | ) | — | |||||||||||
| Adjusted EBITDA | $ | 3,587 | $ | (254 | ) | $ | 3,276 | $ | (89 | ) | ||||||
| LENSAR, Inc. STATEMENTS OF OPERATIONS (In thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Product | $ | 13,042 | $ | 10,910 | $ | 23,118 | $ | 21,828 | ||||||||
| Lease | 1,772 | 1,645 | 3,453 | 3,529 | ||||||||||||
| Service | 1,681 | 1,380 | 3,352 | 2,737 | ||||||||||||
| Total revenue | 16,495 | 13,935 | 29,923 | 28,094 | ||||||||||||
| Cost of revenue (exclusive of amortization) | ||||||||||||||||
| Product | 3,839 | 4,315 | 7,786 | 8,781 | ||||||||||||
| Lease | 851 | 859 | 1,740 | 1,689 | ||||||||||||
| Service | 2,029 | 1,737 | 4,239 | 3,475 | ||||||||||||
| Total cost of revenue | 6,719 | 6,911 | 13,765 | 13,945 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative expenses | 6,141 | 11,658 | 8,670 | 22,807 | ||||||||||||
| Research and development expenses | 1,273 | 1,425 | 2,658 | 2,959 | ||||||||||||
| Amortization of intangible assets | 228 | 230 | 457 | 462 | ||||||||||||
| Total operating expenses | 7,642 | 13,313 | 11,785 | 26,228 | ||||||||||||
| Operating income (loss) | 2,134 | (6,289 | ) | 4,373 | (12,079 | ) | ||||||||||
| Other income (expense) | ||||||||||||||||
| Change in fair value of warrant liabilities | 1,230 | 4,332 | 25,178 | (17,382 | ) | |||||||||||
| Acquisition-related income | — | — | 10,000 | — | ||||||||||||
| Other income, net | 171 | 193 | 316 | 352 | ||||||||||||
| Net income (loss) | 3,535 | (1,764 | ) | 39,867 | (29,109 | ) | ||||||||||
| Other comprehensive income (loss) | ||||||||||||||||
| Change in unrealized loss on investments | — | (6 | ) | (4 | ) | (9 | ) | |||||||||
| Net income (loss) and comprehensive income (loss) | $ | 3,535 | $ | (1,770 | ) | $ | 39,863 | $ | (29,118 | ) | ||||||
| Income (loss) per common share: | ||||||||||||||||
| Basic | $ | 0.14 | $ | (0.15 | ) | $ | 1.62 | $ | (2.46 | ) | ||||||
| Diluted | $ | 0.10 | $ | (0.15 | ) | $ | 0.61 | $ | (2.46 | ) | ||||||
| Weighted-average number of common shares used in calculation of net income (loss) per common share: | ||||||||||||||||
| Basic | 12,297 | 11,937 | 12,230 | 11,856 | ||||||||||||
| Diluted | 23,027 | 11,937 | 24,024 | 11,856 | ||||||||||||
| LENSAR, Inc. BALANCE SHEETS (In thousands, except per share amounts) | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,565 | $ | 12,974 | ||||
| Short-term investments | — | 5,004 | ||||||
| Accounts receivable, net of allowance of | 6,170 | 6,377 | ||||||
| Notes receivable, net of allowance of | 501 | 295 | ||||||
| Inventories | 24,871 | 21,520 | ||||||
| Prepaid and other current assets | 1,919 | 601 | ||||||
| Total current assets | 47,026 | 46,771 | ||||||
| Property and equipment, net | 445 | 505 | ||||||
| Equipment under lease, net | 14,414 | 15,485 | ||||||
| Notes and other receivables, long-term, net of allowance of | 582 | 731 | ||||||
| Intangible assets, net | 4,734 | 5,191 | ||||||
| Other assets | 2,357 | 2,747 | ||||||
| Total assets | $ | 69,558 | $ | 71,430 | ||||
| Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 11,193 | $ | 18,982 | ||||
| Accrued liabilities | 4,728 | 7,771 | ||||||
| Deferred revenue | 2,927 | 3,074 | ||||||
| Operating lease liabilities | 792 | 747 | ||||||
| Acquisition-related deposit | — | 10,000 | ||||||
| Total current liabilities | 19,640 | 40,574 | ||||||
| Long-term accounts payable | 3,750 | — | ||||||
| Long-term operating lease liabilities | 1,589 | 1,988 | ||||||
| Warrant liabilities | 15,016 | 40,194 | ||||||
| Other long-term liabilities | 874 | 909 | ||||||
| Total liabilities | 40,869 | 83,665 | ||||||
| Series A Redeemable Convertible Preferred Stock, par value | 13,784 | 13,784 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, par value | — | — | ||||||
| Common stock, par value | 123 | 120 | ||||||
| Additional paid-in capital | 152,490 | 151,432 | ||||||
| Accumulated other comprehensive income | — | 4 | ||||||
| Accumulated deficit | (137,708 | ) | (177,575 | ) | ||||
| Total stockholders’ equity (deficit) | 14,905 | (26,019 | ) | |||||
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $ | 69,558 | $ | 71,430 | ||||
